Skip to main content

Advertisement

SpringerLink
Log in

Impact of Lifestyle Modification on Diabetic Kidney Disease

  • Microvascular Complications—Nephropathy (T Isakova, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Kidney disease is common in patients with type 1 and type 2 diabetes mellitus and is associated with adverse health outcomes, including progression to end-stage renal disease. In the general population, adherence to a healthy lifestyle is known to reduce the risk of cardiovascular events and death. Among individuals with diabetic kidney disease, modifications in lifestyle factors, including diet, physical activity, smoking habits, and body mass index, represent a promising cost-effective therapeutic adjunct to pharmacologic treatment of kidney disease incidence and progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis Off J Natl Kidney Found. 1996;27:167–94.

    Article  CAS  Google Scholar 

  2. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127–33.

    Article  CAS  PubMed  Google Scholar 

  3. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2014;63:S3–21. This paper provides a comprehensive review of the epidemiology of diabetic kidney disease.

    Article  Google Scholar 

  4. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2014;63:S39–62.

    Article  Google Scholar 

  5. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol JASN. 2013;24:302–8.

    Article  CAS  PubMed  Google Scholar 

  6. Muntner P, Bowling CB, Gao L, Rizk D, Judd S, Tanner RM, et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin J Am Soc Nephrol CJASN. 2011;6:2200–7.

    Article  CAS  PubMed  Google Scholar 

  7. Jude EB, Anderson SG, Cruickshank JK, Srivatsa A, Tentolouris N, Chandrasekaran R, et al. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. QJM Mon J Assoc Physicians. 2002;95:371–7.

    Article  CAS  Google Scholar 

  8. Loef M, Walach H. The combined effects of healthy lifestyle behaviors on all cause mortality: a systematic review and meta-analysis. Prev Med. 2012;55:163–70.

    Article  PubMed  Google Scholar 

  9. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation. 2006;114:160–7.

    Article  PubMed  Google Scholar 

  10. Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, et al. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 2011;306:62–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Ricardo AC, Madero M, Yang W, Anderson C, Menezes M, Fischer MJ, et al. Adherence to a healthy lifestyle and all-cause mortality in CKD. Clin J Am Soc Nephrol CJASN. 2013;8:602–9.

    Article  PubMed  Google Scholar 

  12. Ricardo AC, Anderson CA, Yang W, Zhang X, Fischer MJ, Dember LM, et al. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis Off J Natl Kidney Found. 2015;65:412–24.

    Article  Google Scholar 

  13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1–150.

    Article  Google Scholar 

  14. Shapiro H, Theilla M, Attal-Singer J, Singer P. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol. 2011;7:110–21.

    Article  CAS  PubMed  Google Scholar 

  15. Suckling RJ, He FJ, Macgregor GA. Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database Syst Rev. 2010;CD006763.

  16. Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care. 2002;25:663–71.

    Article  CAS  PubMed  Google Scholar 

  17. Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996;125:201–4.

    Article  CAS  PubMed  Google Scholar 

  18. Esnault VLM, Ekhlas A, Delcroix C, Moutel M-G, Nguyen J-M. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol JASN. 2005;16:474–81.

    Article  CAS  PubMed  Google Scholar 

  19. Wen SF, Huang TP, Moorthy AV. Effects of low-protein diet on experimental diabetic nephropathy in the rat. J Lab Clin Med. 1985;106:589–97.

    CAS  PubMed  Google Scholar 

  20. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–9.

    Article  CAS  PubMed  Google Scholar 

  21. Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am J Physiol. 1987;253:F1083–90.

    CAS  PubMed  Google Scholar 

  22. Rosenberg ME, Chmielewski D, Hostetter TH. Effect of dietary protein on rat renin and angiotensinogen gene expression. J Clin Invest. 1990;85:1144–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Pijls LT, de Vries H, Donker AJ, van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 1999;14:1445–53.

    CAS  Google Scholar 

  24. Pijls LTJ, de Vries H, van Eijk JTM, Donker AJM. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr. 2002;56:1200–7.

    Article  CAS  PubMed  Google Scholar 

  25. Velázquez López L, Sil Acosta MJ, Goycochea Robles MV, Torres Tamayo M, Castañeda Limones R. Effect of protein restriction diet on renal function and metabolic control in patients with type 2 diabetes: a randomized clinical trial. Nutr Hosp. 2008;23:141–7.

    PubMed  Google Scholar 

  26. Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H, et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia. 2009;52:2037–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Dussol B, Iovanna C, Raccah D, Darmon P, Morange S, Vague P, et al. A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2005;15:398–406.

    Article  Google Scholar 

  28. Hansen HP, Tauber-Lassen E, Jensen BR, Parving H-H. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220–8.

    Article  PubMed  Google Scholar 

  29. Raal FJ, Kalk WJ, Lawson M, Esser JD, Buys R, Fourie L, et al. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994;60:579–85.

    CAS  PubMed  Google Scholar 

  30. Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open. 2013;3. This meta-analysis summarizes 13 randomized trials of the effect of low-protein diet on diabetic kidney disease.

  31. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:660–6.

    CAS  PubMed  Google Scholar 

  32. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol JASN. 2012;23:165–73.

    Article  CAS  PubMed  Google Scholar 

  33. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2007;49:S12–154.

    Article  Google Scholar 

  34. Salem MA, Aboelasrar MA, Elbarbary NS, Elhilaly RA, Refaat YM. Is exercise a therapeutic tool for improvement of cardiovascular risk factors in adolescents with type 1 diabetes mellitus? A randomised controlled trial. Diabetol Metab Syndr. 2010;2:47.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Lehmann R, Kaplan V, Bingisser R, Bloch KE, Spinas GA. Impact of physical activity on cardiovascular risk factors in IDDM. Diabetes Care. 1997;20:1603–11.

    Article  CAS  PubMed  Google Scholar 

  36. Ishii T, Yamakita T, Sato T, Tanaka S, Fujii S. Resistance training improves insulin sensitivity in NIDDM subjects without altering maximal oxygen uptake. Diabetes Care. 1998;21:1353–5.

    Article  CAS  PubMed  Google Scholar 

  37. Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107:2435–9.

    Article  PubMed  Google Scholar 

  38. Tufescu A, Kanazawa M, Ishida A, Lu H, Sasaki Y, Ootaka T, et al. Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy. J Hypertens. 2008;26:312–21.

    Article  CAS  PubMed  Google Scholar 

  39. Wadén J, Tikkanen HK, Forsblom C, Harjutsalo V, Thorn LM, Saraheimo M, et al. Leisure-time physical activity and development and progression of diabetic nephropathy in type 1 diabetes: the FinnDiane Study. Diabetologia. 2015;58:929–36. Cohort study evaluating the impact of physical activity on diabetic nephropathy.

    Article  PubMed  Google Scholar 

  40. Wadén J, Forsblom C, Thorn LM, Saraheimo M, Rosengård-Bärlund M, Heikkilä O, et al. Physical activity and diabetes complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) study. Diabetes Care. 2008;31:230–2.

    Article  PubMed  Google Scholar 

  41. Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, et al. Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney Int. 2015;87:784–91. Large observational study of the association of smoking and physical activity of progression of diabetic kidney disease.

    Article  CAS  PubMed  Google Scholar 

  42. Kriska AM, LaPorte RE, Patrick SL, Kuller LH, Orchard TJ. The association of physical activity and diabetic complications in individuals with insulin-dependent diabetes mellitus: the Epidemiology of Diabetes Complications Study—VII. J Clin Epidemiol. 1991;44:1207–14.

    Article  CAS  PubMed  Google Scholar 

  43. Makura CB, Nirantharakumar K, Girling AJ, Saravanan P, Narendran P. Effects of physical activity on the development and progression of microvascular complications in type 1 diabetes: retrospective analysis of the DCCT study. BMC Endocr Disord. 2013;13:37.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH, American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S73–7.

    PubMed  Google Scholar 

  45. Brazeau A-S, Rabasa-Lhoret R, Strychar I, Mircescu H. Barriers to physical activity among patients with type 1 diabetes. Diabetes Care. 2008;31:2108–9.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Thomas N, Alder E, Leese GP. Barriers to physical activity in patients with diabetes. Postgrad Med J. 2004;80:287–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Heitzer T, Just H, Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996;94:6–9.

    Article  CAS  PubMed  Google Scholar 

  48. Phisitkul K, Hegazy K, Chuahirun T, Hudson C, Simoni J, Rajab H, et al. Continued smoking exacerbates but cessation ameliorates progression of early type 2 diabetic nephropathy. Am J Med Sci. 2008;335:284–91.

    Article  PubMed  Google Scholar 

  49. Esmatjes E, Flores L, Lario S, Clària J, Cases A, Iñigo P, et al. Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care. 1999;22:1915–6.

    Article  CAS  PubMed  Google Scholar 

  50. Mur C, Clària J, Rodela S, Lario S, Campistol JM, Titos E, et al. Cigarette smoke concentrate increases 8-epi-PGF2alpha and TGFbeta1 secretion in rat mesangial cells. Life Sci. 2004;75:611–21.

    Article  CAS  PubMed  Google Scholar 

  51. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149–55.

    Article  CAS  PubMed  Google Scholar 

  52. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334:150–4.

    Article  CAS  PubMed  Google Scholar 

  53. Lhotta K, Rumpelt HJ, König P, Mayer G, Kronenberg F. Cigarette smoking and vascular pathology in renal biopsies. Kidney Int. 2002;61:648–54.

    Article  PubMed  Google Scholar 

  54. Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol. 2002;33:826–35.

    Article  PubMed  Google Scholar 

  55. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care. 1978;1:146–9.

    Article  CAS  PubMed  Google Scholar 

  56. Parving H-H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG, DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006;69:2057–63.

    Article  PubMed  Google Scholar 

  57. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA. 1991;265:614–7.

    Article  CAS  PubMed  Google Scholar 

  58. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care. 1995;18:785–92.

    Article  CAS  PubMed  Google Scholar 

  59. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ. 1993;306:1235–9.

  60. Rossing P, Hougaard P, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care. 2002;25:859–64.

    Article  PubMed  Google Scholar 

  61. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126–31.

    Article  CAS  PubMed  Google Scholar 

  62. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1997;40:405–11.

    Article  CAS  PubMed  Google Scholar 

  63. De Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol JASN. 2007;18:235–43.

    Article  PubMed  Google Scholar 

  64. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving H-H. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66:1596–605.

    Article  PubMed  Google Scholar 

  65. Hovind P, Rossing P, Tarnow L, Parving H-H. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2003;26:911–6.

    Article  PubMed  Google Scholar 

  66. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–9.

    Article  CAS  PubMed  Google Scholar 

  67. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:69–75.

    Article  CAS  PubMed  Google Scholar 

  68. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–105.

    Article  CAS  PubMed  Google Scholar 

  69. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230–5.

    Article  CAS  PubMed  Google Scholar 

  70. Cameron AJ, Magliano DJ, Söderberg S. A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. Obes Rev Off J Int Assoc Study Obes. 2013;14:86–94.

    Article  CAS  Google Scholar 

  71. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555–63.

    CAS  PubMed  Google Scholar 

  72. Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013;33:23–33.

    Article  PubMed  Google Scholar 

  73. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.

    Article  CAS  PubMed  Google Scholar 

  74. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278:F817–22.

    CAS  PubMed  Google Scholar 

  75. Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97:59–74.

    Article  PubMed Central  PubMed  Google Scholar 

  76. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28:2019–24.

    Article  PubMed  Google Scholar 

  77. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.

    Article  PubMed  Google Scholar 

  78. Huang W-H, Chen C-Y, Lin J-L, Lin-Tan D-T, Hsu C-W, Yen T-H. High body mass index reduces glomerular filtration rate decline in type II diabetes mellitus patients with stage 3 or 4 chronic kidney disease. Medicine (Baltimore). 2014;93:e41.

    Article  Google Scholar 

  79. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol CJASN. 2012;7:401–8.

    Article  CAS  PubMed  Google Scholar 

  80. Mohsen A, Brown R, Hoefield R, Kalra PA, O’Donoghue D, Middleton R, et al. Body mass index has no effect on rate of progression of chronic kidney disease in subjects with type 2 diabetes mellitus. J Nephrol. 2012;25:384–93.

    Article  PubMed  Google Scholar 

  81. Friedman AN, Chambers M, Kamendulis LM, Temmerman J. Short-term changes after a weight reduction intervention in advanced diabetic nephropathy. Clin J Am Soc Nephrol CJASN. 2013;8:1892–8.

    Article  CAS  PubMed  Google Scholar 

  82. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes. 2005;29:1115–20.

    Article  CAS  Google Scholar 

  83. Heneghan HM, Cetin D, Navaneethan SD, Orzech N, Brethauer SA, Schauer PR. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2013;9:7–14. Retrospective study of long-term effects of weight loss on diabetic nephropathy.

    Article  Google Scholar 

  84. Stephenson DT, Jandeleit-Dahm K, Balkau B, Cohen N. Improvement in albuminuria in patients with type 2 diabetes after laparoscopic adjustable gastric banding. Diab Vasc Dis Res. 2013;10:514–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Ana C. Ricardo is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK094829).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Chijoke Onyenwenyi declares no conflict of interest.

Ana C. Ricardo reports personal fees from Keryx Biopharmaceuticals.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Nephrology, The University of Illinois at Chicago, 820 South Wood Street, 418W CSN, MC 793, Chicago, IL, 60612, USA

    Chijoke Onyenwenyi & Ana C. Ricardo

Authors
  1. Chijoke Onyenwenyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana C. Ricardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana C. Ricardo.

Additional information

This article is part of the Topical Collection on Microvascular Complications—Nephropathy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onyenwenyi, C., Ricardo, A.C. Impact of Lifestyle Modification on Diabetic Kidney Disease. Curr Diab Rep 15, 60 (2015). https://doi.org/10.1007/s11892-015-0632-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-015-0632-3

Keywords

Search

Navigation